Drug Profile
ISIS 22023
Latest Information Update: 27 Jan 2004
Price :
$50
*
At a glance
- Originator Isis Pharmaceuticals
- Class Antisense oligonucleotides; Hepatoprotectants
- Mechanism of Action Genetic transcription inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Liver disorders
Most Recent Events
- 27 Jan 2004 No development reported - Preclinical for Liver disorders in USA (unspecified route)
- 14 Mar 2001 New profile
- 14 Mar 2001 Preclinical development for Liver disorders in USA (Unknown route)